Suven Pharmaceuticals Ltd share price logo

Suven Pharmaceuticals Ltd Share Price

(SUVENPHAR)

Small Cap

Healthcare Sector

₹1181.6▲1.16%

as on 11:33AM, 21 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Suven Pharmaceuticals Ltd Performance

  • Day's Low

    Day's High

    ₹1,157.9
    Day's Price Range
    ₹1,193.9

  • 52 Week's Low

    52 Week's High

    ₹598
    52-Week Price Range
    ₹1,360
1 Month Return-3.56 %
3 Month Return+ 10.86 %
1 Year Return+ 83.25 %
Previous Close₹1,168.10
Open₹1,184.60
Volume67.13K
Upper Circuit₹1,401.70
Lower Circuit₹934.50
Market Cap₹29,735.73Cr

Suven Pharmaceuticals Ltd Fundamentals

P/E Ratio

106.38

PEG Ratio

-29.55

Market Cap

₹29,735.73 Cr

P/B Ratio

8.38

EPS

11.8

Dividend Yield

0

Sector

Pharmaceuticals

ROE

14.31

Suven Pharmaceuticals Ltd Analyst Rating

based on 6 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 6 analysts offering long term price targets for Suven Pharmaceuticals Ltd. An average target of ₹1396.67

Source: S&P Global Market Intelligence

Suven Pharmaceuticals Ltd Share analysis

Suven Pharmaceuticals Ltd price forecast by 6 analysts

Upside of19.57%

High

₹1500

Target

₹1396.67

Low

₹1290

Suven Pharmaceuticals Ltd target price ₹1396.67, a slight upside of 19.57% compared to current price of ₹1181.6. According to 6 analysts rating.

Source: S&P Global Market Intelligence

Key events for Suven Pharmaceuticals Ltd

  • Goldman Sachs Initiates Buy Rating for Suven Pharma - 08 Apr, 2025

    Goldman Sachs has initiated coverage on Suven Pharmaceuticals with a Buy rating and a target price of ₹1,350, anticipating structural growth starting FY26 driven by key drugs and successful acquisitions. The brokerage projects over 20% CAGR in EBITDA for the combined entity, highlighting a strong recovery path and improving profitability.

  • Suven Pharmaceuticals Receives NSE Caution on Disclosure - 02 Apr, 2025

    Suven Pharmaceuticals Ltd received a caution from the NSE for delaying the disclosure of its Statutory Auditors' appointment. The company assures no impact on its operations and commits to future compliance with SEBI regulations.

  • Suven Pharmaceuticals Merges with Cohance Lifesciences - 28 Mar, 2025

    Suven Pharmaceuticals has received NCLT approval for its merger with Cohance Lifesciences, creating a diversified CDMO platform. The merger aims to enhance global capabilities and is expected to generate $1 billion in revenue within five years.

  • ICICI Securities Initiates Buy Rating on Suven Pharmaceuticals - 25 Mar, 2025

    ICICI Securities has initiated coverage on Suven Pharmaceuticals with a BUY rating and a target price of INR 1,400. The company is poised for significant growth in the CDMO space, driven by its merger with Cohance and strategic acquisitions. Management aims for USD 1 billion in revenue by FY30, with strong projected growth rates.

Insights on Suven Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 10.70% to 10.84% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 248.85 Cr → 322.86 Cr (in ₹), with an average increase of 12.1% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 5 quarters, 46.75 Cr → 82.88 Cr (in ₹), with an average increase of 12.9% per quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 22.25% to 22.37% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, SUVENPHAR stock has moved up by 10.9%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, SUVENPHAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 50.10% of holdings in Dec 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 130.0% return, outperforming this stock by 26.6%

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 14.12% to 13.15% in Dec 2024 quarter

Suven Pharmaceuticals Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹219.82Cr (-)₹252.93Cr (↑15.06%)₹230.69Cr (↓8.79%)₹257.72Cr (↑11.72%)₹307.15Cr (↑19.18%)
Net Income₹46.75Cr (-)₹53.37Cr (↑14.16%)₹60.77Cr (↑13.87%)₹81.98Cr (↑34.90%)₹83.29Cr (↑1.60%)
Net Profit Margin21.27% (-)21.10% (↓0.80%)26.34% (↑24.83%)31.81% (↑20.77%)27.12% (↓14.74%)
Value in ₹ crore
Details2021202220232024
Total Assets₹1,361.30Cr (-)₹1,806.37Cr (↑32.69%)₹1,959.73Cr (↑8.49%)₹2,244.38Cr (↑14.52%)
Total Liabilities₹296.11Cr (-)₹285.67Cr (↓3.53%)₹210.35Cr (↓26.37%)₹188.48Cr (↓10.40%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹358.75Cr (-)₹328.84Cr (↓8.34%)₹269.89Cr (↓17.93%)₹492.82Cr (↑82.60%)₹370.65Cr (↓24.79%)

Suven Pharmaceuticals Ltd Index Inclusions

Nifty Smallcap 250

₹15,684.50

1.5 (▲232.4%)

S&P BSE 250 SmallCap

₹6,268.81

1.5 (▲92.52%)

BSE 500

₹34,553.25

1.3 (▲443.58%)

Nifty 500

₹21,969.40

1.33 (▲287.85%)

BSE Healthcare

₹41,853.79

0.38 (▲156.67%)

S&P BSE SmallCap Select

₹7,152.87

1.79 (▲125.61%)

S&P BSE 400 MidSmallCap

₹11,131.76

1.63 (▲178.25%)

Nifty MNC

₹26,877.25

0.65 (▲173.3%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

Nifty MidSmallcap 400

₹18,314.30

1.7 (▲305.4%)

BSE Small-Cap

₹48,581.89

1.32 (▲635.23%)

Suven Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
50.1%
0.00
Foreign Institutions
10.84%
1.34
Mutual Funds
13.15%
-6.81
Retail Investors
22.37%
0.52
Others
3.54%
24.73

Suven Pharmaceuticals Ltd Key Indicators

Details20202021202220232024
Return On Equity %39.7133.443.1726.4614.31
Details20202021202220232024
Return On Assets %28.4926.6225.1220.9913.38
Details20202021202220232024
Book Value Per Share (₹)33.1946.3859.9968.1680.56
Details20202021202220232024
Earning Per Share (₹)12.4614.2317.8316.1611.8

Suven Pharmaceuticals Ltd Valuation

Suven Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (4.48x)

March 30, 2020

Industry (53.02x)

April 17, 2025

Today (106.38x)

April 17, 2025

Highest (139.56x)

November 5, 2024

LowHigh

Suven Pharmaceuticals Ltd Earnings and Dividends

  • Suven Pharmaceuticals Ltd Earnings Results

    Suven Pharmaceuticals Ltd’s net profit jumped 77.28% since last year same period to ₹82.88Cr in the Q3 2024-2025. On a quarterly growth basis, Suven Pharmaceuticals Ltd has generated 0.81% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Suven Pharmaceuticals Ltd Dividends September,2022

    In the quarter ending June 2022, Suven Pharmaceuticals Ltd has declared dividend of ₹1 - translating a dividend yield of 0.94%.

    Read More about Dividends

Suven Pharmaceuticals Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Suven Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.

More on Technical Analysis

Suven Pharmaceuticals Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
BUY₹29,735.73 Cr147.53%0.52₹300 Cr₹1,051 Cr
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
BUY₹14,638.87 Cr40.19%0.57₹72 Cr₹6,702 Cr
Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd
NA₹4,865.55 Cr1.46%0.79-₹388 Cr₹75 Cr
Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Ltd
BUY₹15,265.25 Cr46.78%0.68₹218 Cr₹1,296 Cr
Poly Medicure Ltd
Poly Medicure Ltd
BUY₹24,252.31 Cr186.65%0.55₹258 Cr₹1,375 Cr
See all

About Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Limited (SPL) is a biopharmaceutical company engaged in the development and manufacturing of New Chemical Entity (NCE) based Intermediates and Active Pharmaceutical Ingredients, Speciality Chemicals, and formulated drugs. In 2019, Suven Life Sciences Ltd. transferred the CRAMS business to the Company, and the equity shares of the Company were listed for trading in March 2020. The Board approved and recommended the issue of 1:1 bonus shares in August 2020, and the number of shares increased from 127,282,478 to 254,564,956. In 2021, Suven invested 120 crore in investing and has a capex plan of Rs.320crore. In 2022, the Company also filed 17 ANDAs for which 9 were approved and 8 products were launched. The Company acquired 100 stake in Casper Pharma Private Limited in 2022, making it a Wholly Owned Subsidiary. In this way, Suven Pharmaceuticals Limited is endeavouring to be the leading biopharmaceutical company in global markets.

Revenue: ₹307.15Cr as on December 2024 (Q4 24)
Net Profit: ₹83.29Cr as on December 2024 (Q4 24)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
OrganisationSuven Pharmaceuticals Ltd
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Suven Pharmaceuticals Ltd

What is Suven Pharmaceuticals Ltd price today?

Suven Pharmaceuticals Ltd share price today stands at ₹1181.6, Open: ₹1184.6, Previous Close: ₹1168.1, High: ₹1193.9, Low: ₹1157.9, 52 Week High: ₹1360, 52 Week Low: ₹598.

How to Buy Suven Pharmaceuticals Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Suven Pharmaceuticals Ltd shares

What are today's traded volumes of Suven Pharmaceuticals Ltd?

Today's traded volume of Suven Pharmaceuticals Ltd(SUVENPHAR) is 67.13K.

What is today's market capitalisation of Suven Pharmaceuticals Ltd?

Today's market capitalisation of Suven Pharmaceuticals Ltd(SUVENPHAR) is ₹29735.73Cr.

What is the 52 Week High and Low Range of Suven Pharmaceuticals Ltd?

Suven Pharmaceuticals Ltd (SUVENPHAR)
Price
52 Week High
₹1360
52 Week Low
₹598

How much percentage Suven Pharmaceuticals Ltd is down from its 52 Week High?

Suven Pharmaceuticals Ltd (SUVENPHAR) share price is ₹1181.6. It is down -13.12% from its 52 Week High price of ₹1360

How much percentage Suven Pharmaceuticals Ltd is up from its 52 Week low?

Suven Pharmaceuticals Ltd (SUVENPHAR) share price is ₹1181.6. It is up 97.59% from its 52 Week Low price of ₹598